Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
Cancers|January 11, 2022
A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series StudyGiovanni Vicidomini, Carminia Maria Della Corte, Antonio Noro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 13, 2018
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor ModelsCarminia Maria Della Corte, Vincenza Ciaramella, Claudia Cardone, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 30, 2019
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell linesPietro Paolo Vitiello, Claudia Cardone, Giulia Martini, et al.
Cancers|June 13, 2025
Application of Telepathology for Rapid On-Site Evaluation of Touch Imprint Cytology in CT-Guided Percutaneous Transthoracic Core Needle Biopsy of Pulmonary Nodules: The Experience of Our Multidisciplinary Thoracic Tumor BoardStefano Lucà, Riccardo Monti, Carminia Maria Della Corte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2015
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung CancerCarminia Maria Della Corte, Claudio Bellevicine, Giovanni Vicidomini, et al.
Diagnostics (Basel, Switzerland)|June 12, 2026
When Lymph Nodes Don't Lie: Report of Three Unusual Presentations of Thoracic TumorsStefano Lucà, Francesco Barbato, Amedeo Di Maio, et al.
Therapeutic Advances in Medical Oncology|March 26, 2021
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapyMorena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, et al.
International Journal of Cancer|May 1, 2013
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cellsErika Martinelli, Teresa Troiani, Elena D'Aiuto, et al.
ESMO Open|September 11, 2020
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancerMorena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, et al.
RSC Medicinal Chemistry|November 8, 2024
Discovery of <i>N</i>-substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancerStefano Tomassi, Benito Natale, Michele Roggia, et al.
Pageof 16